keyword
MENU ▼
Read by QxMD icon Read
search

hepatitis B antiviral therapy

keyword
https://www.readbyqxmd.com/read/28634402/enhanced-antiviral-and-antifibrotic-effects-of-short-hairpin-rnas-targeting-hbv-and-tgf-%C3%AE-in-hbv-persistent-mice
#1
Lei Ye, Fangming Kan, Tao Yan, Jiaqi Cao, Leiliang Zhang, Zhijian Wu, Wuping Li
The hepatitis B virus (HBV) causes acute and chronic liver infection, which may lead to liver cirrhosis and hepatocellular carcinoma. Current treatments including interferons and nucleotide analogs, have limited therapeutic effects, underscoring the need to identify effective therapeutic options to inhibit HBV replication and prevent complications. Previous animal models mimicking chronic HBV infection do not faithfully reflect disease progression in humans. Here, we used our established HBV-persistent mouse line with liver fibrosis to evaluate the efficacy of novel therapies...
June 20, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28633752/rituximab-administration-in-a-patient-with-pemphigus-vulgaris-following-reactivation-of-occult-hepatitis-b-virus-infection
#2
Soheil Tavakolpour, Tahereh Soori, Pedram Noormohammadpour, Kamran Balighi, Hamidreza Mahmoudi, Maryam Daneshpazhooh
Immunosuppressive drugs are the milestone of treatment of autoimmune diseases, but they can lead to serious complications, including hepatitis B virus reactivation in HBV carriers as well as in patients with occult HBV infection (OBI). A 36-year-old man with OBI was diagnosed with pemphigus vulgaris. He was prescribed prednisolone and his hepatitis B surface antigen turned positive. Viral replication was successfully controlled by lamivudine and adefovir. Mycophenolate mofetil and intravenous immunoglobulin  were not effective in controlling the pemphigus vulgaris...
June 20, 2017: Dermatology Online Journal
https://www.readbyqxmd.com/read/28632974/hcv-positive-donor-organs-in-solid-organ-transplantation-mind-the-gap
#3
EDITORIAL
J A Fishman, X Forns
The shortage of organs for transplantation is a major impediment to access to life-saving therapy. The availability of antiviral therapies that control hepatitis B (HBV) and HIV, or cure hepatitis C (HCV), have changed traditional equations in transplantation, allowing infected individuals access to transplantation without unimpeded viral replication during immunosuppression. The availability of these therapies also permits use of organs from donors actively or potentially infected with these viruses. This article is protected by copyright...
June 20, 2017: American Journal of Transplantation
https://www.readbyqxmd.com/read/28632923/comparing-the-risk-of-hepatitis-b-virus-reactivation-between-direct-acting-antiviral-therapies-and-interferon-based-therapies-for-hepatitis-c
#4
Naoki Kawagishi, Goki Suda, Masahiro Onozawa, Megumi Kimura, Osamu Maehara, Masatsugu Ohara, Takaaki Izumi, Machiko Umemura, Jun Ito, Masato Nakai, Takuya Sho, Mitsuteru Natsuizka, Kenichi Morikawa, Koji Ogawa, Naoya Sakamoto
BACKGROUND: Hepatitis B virus (HBV)-reactivation has been reported during anti-hepatitis C treatment in patients with hepatitis C virus (HCV) and HBV co-infection. We aimed to evaluate the frequency and risk factors of HBV-reactivation during anti-HCV therapy and compared those between interferon (IFN)-free direct-acting antiviral (DAA)-therapies and IFN-based therapies. METHODS: 322 patients with HCV infection receiving anti-HCV therapy were retrospectively screened...
June 20, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28631698/-hepatitis-c-virus-associated-cryoglobulinemic-vasculitis-a-20-year-experience-with-treatment
#5
T M Ignatova, L V Kozlovskaya, N B Gordovskaya, O A Chernova, S Yu Milovanova, P I Novikov, T P Nekrasova, T V Beketova, N A Mukhin
AIM: To summarize the experience of a multidisciplinary therapy hospital in treating patients with hepatitis C virus (HCV)-associated cryoglobulinemic vasculitis (CV). SUBJECTS AND METHODS: Seventy-two patients (mean age, 49.4±10.3 years) with HCV-associated CV were examined and followed up for an average period of 2.8±3.6 years. The efficiency of traditional (corticosteroids ± cyclophosphamide) and selective (rituximab) immunosuppressive therapy (IST) was estimated in 31 and 15 observations, respectively, and that of antiviral therapy (AVT) in 25...
2017: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/28631044/-personalized-treatment-of-viral-hepatitis-of-the-present-and-the-future-hepatitis%C3%A2-b-c-delta-and-e
#6
REVIEW
R Bartenschlager, M Cornberg, T Pietschmann
Precision medicine is also possible for infectious diseases as shown for the treatment of chronic viral hepatitis, especially if different options are available. In hepatitis B virus (HBV) infection, treatment indication as well as the choice of treatment and the decisions to stop treatment are based on viral markers and alanine aminotransferase (ALT) level. Future therapies for HBV infection aiming for functional cure or even virus elimination may be even more personalized and have to take into account the immune status of a given patient...
June 19, 2017: Der Internist
https://www.readbyqxmd.com/read/28629395/early-experiences-from-one-of-the-first-treatment-programs-for-chronic-hepatitis-b-in-sub-saharan-africa
#7
Hanna Aberra, Hailemichael Desalegn, Nega Berhe, Girmay Medhin, Kathrine Stene-Johansen, Svein Gunnar Gundersen, Asgeir Johannessen
BACKGROUND: Treatment for chronic hepatitis B (CHB) is virtually absent in sub-Saharan Africa. Here we present early experiences from a pilot program for treatment of CHB in Ethiopia. METHODS: Adults (≥18 years) with CHB were included in a cohort study at St. Paul's Hospital Millennium Medical College, Addis Ababa, from February 2015. The baseline assessment included liver function tests, viral markers and transient elastography (Fibroscan 402, Echosense, France)...
June 19, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28628729/pre-and-post-operative-hbsag-levels-may-predict-recurrence-and-survival-after-curative-resection-in-patients-with-hbv-associated-hepatocellular-carcinoma
#8
Jing-Feng Qiu, Jia-Zhou Ye, Xu-Zhuo Feng, Ya-Peng Qi, Liang Ma, Wei-Ping Yuan, Jian-Hong Zhong, Zhi-Ming Zhang, Bang-De Xiang, Le-Qun Li
PURPOSE: To investigate pre- and post-operative levels of HBsAg influence prognosis of patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) after curative resection. METHODS: Medical records were retrospectively analyzed for 881 patients with HBV-related HCC treated by curative resection. Patients were classified as having high or low serum HBsAg levels (≥200 or <200 ng/mL) pre- or post-operatively. RESULTS: OS and RFS were better for patients with low pre-operative serum levels of HBsAg than for those with high levels...
June 19, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28627791/no-evidence-of-hepatitis-b-virus-reactivation-in-patients-with-resolved-infection-treated-with-direct-acting-antivirals-for-hepatitis-c-in-a-large-real-world-cohort
#9
V T Mücke, M M Mücke, K-H Peiffer, N Weiler, T M Welzel, C Sarrazin, S Zeuzem, A Berger, J Vermehren
BACKGROUND: Hepatitis B virus (HBV) reactivation has been observed following interferon (IFN)-based treatment in HBV/hepatitis C virus (HCV) co-infected patients. Recent reports suggest that reactivation may also occur in both hepatitis B surface antigen (HBsAg)-positive and HBsAg-negative patients during HCV treatment with direct-acting antivirals (DAAs). AIM: To investigate the rate of patients with HBV reactivation during IFN-based and IFN-free HCV treatment in a large real-world cohort...
June 19, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28627393/the-potential-and-challenges-of-crispr-cas-in-eradication-of-hepatitis-b-virus-covalently-closed-circular-dna
#10
REVIEW
Hung-Chih Yang, Pei-Jer Chen
Current antiviral therapy fails to cure chronic hepatitis B virus (HBV) infection, primarily because of the persistence of covalently closed circular DNA (cccDNA). Although nucleos(t)ide analogues (NAs) can inhibit the reverse transcriptase of HBV and suppress its replication to levels below the detection limit, viremia often rebounds after cessation of therapy. Nuclear cccDNA serves as the HBV replicative template and exhibits extraordinary stability, and is not affected by NAs. Therefore, curing chronic hepatitis B (CHB) requires novel therapy for purging cccDNA from patients...
June 13, 2017: Virus Research
https://www.readbyqxmd.com/read/28624460/identification-of-kx2-391-as-an-inhibitor-of-hbv-transcription-by-a-recombinant-hbv-based-screening-assay
#11
Keisuke Harada, Hironori Nishitsuji, Saneyuki Ujino, Kunitada Shimotohno
Antiviral therapies for chronic hepatitis B virus (HBV) infection that are currently applicable for clinical use are limited to nucleos(t)ide analogs targeting HBV polymerase activity and pegylated interferon alpha (PEG-IFN). Towards establishing an effective therapy for HBV related diseases, it is important to develop a new anti-HBV agent that suppresses and eradicates HBV. This study used recombinant HBV encoding NanoLuc to screen anti-HBV compounds from 1827 US Food and Drug Administration approved compounds and identified several compounds that suppressed HBV infection...
June 15, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28617992/antiplatelet-therapy-and-the-risk-of-hepatocellular-carcinoma-in-chronic-hepatitis-b-patients-on-antiviral-treatment
#12
Minjong Lee, Goh Eun Chung, Jeong-Hoon Lee, Sohee Oh, Joon Yeul Nam, Young Chang, Hyeki Cho, Hongkeun Ahn, Young Youn Cho, Jeong-Ju Yoo, Yuri Cho, Dong Hyeon Lee, Eun Ju Cho, Su Jong Yu, Dong Ho Lee, Jeong Min Lee, Yoon Jun Kim, Jung-Hwan Yoon
Antiplatelet therapy has shown protective effects against hepatocellular carcinoma (HCC) in preclinical studies. However, it is unclear whether antiplatelet therapy lowers the risk of HCC in patients with chronic hepatitis B (CHB). A retrospective analysis was conducted of data from 1,674 CHB patients, enrolled between January 2002 and May 2015, whose serum hepatitis B virus (HBV) DNA levels were suppressed by antivirals to <2,000 IU/mL. The primary and secondary outcomes were development of HCC and bleeding events, respectively...
June 15, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28614914/ip-10-expression-in-patients-with-chronic-hbv-infection-and-its-ability-to-predict-the-decrease-in-hbsag-levels-after-treatment-with-entecavir
#13
Kai Zhao, Tao Yang, Mimi Sun, Wei Zhang, Yong An, Gang Chen, Lei Jin, Qinghua Shang, Wengang Song
Interferon-γ-inducible protein 10 (IP-10), also known as chemokine C-X-C motif ligand (CXCL) 10, is closely associated with antiviral immunity and the progression of chronic hepatitis B (CHB). However, the value of baseline serological and histological IP-10 expression levels in predicting the efficacy of the antiviral response to nucleoside/nucleotide analogues (NAs) is still unknown. In our research, intrahepatic and peripheral IP-10 expression levels were systemically examined before and after treatment with entecavir (ETV)...
June 14, 2017: Molecules and Cells
https://www.readbyqxmd.com/read/28611778/peg-interferon-lambda-treatment-induces-robust-innate-and-adaptive-immunity-in-chronic-hepatitis-b-patients
#14
Sandra Phillips, Sameer Mistry, Antonio Riva, Helen Cooksley, Tanya Hadzhiolova-Lebeau, Slava Plavova, Krum Katzarov, Marieta Simonova, Stephan Zeuzem, Clive Woffendin, Pei-Jer Chen, Cheng-Yuan Peng, Ting-Tsung Chang, Stefan Lueth, Robert De Knegt, Moon-Seok Choi, Heiner Wedemeyer, Michael Dao, Chang-Wook Kim, Heng-Chen Chu, Megan Wind-Rotolo, Roger Williams, Elizabeth Cooney, Shilpa Chokshi
IFN-lambda (IFNλ) is a member of the type III IFN family and is reported to possess anti-pathogen, anti-cancer, and immunomodulatory properties; however, there are limited data regarding its impact on host immune responses in vivo. We performed longitudinal and comprehensive immunosurveillance to assess the ability of pegylated (peg)-IFNλ to augment antiviral host immunity as part of a clinical trial assessing the efficacy of peg-IFNλ in chronic hepatitis B (CHB) patients. These patients were pretreated with directly acting antiviral therapy (entecavir) for 12 weeks with subsequent addition of peg-IFNλ for up to 32 weeks...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28591041/relationship-of-treg-th17-balance-with-hbeag-change-in-hbeag-positive-chronic-hepatitis-b-patients-receiving-telbivudine-antiviral-treatment-a-longitudinal-observational-study
#15
Xiaoling Yang, Jia Li, Jie Liu, Min Gao, Li Zhou, Wei Lu
Telbivudine (LdT) is an orally L-nucleoside with potent and specific antihepatitis B virus (HBV) activity. The higher rate of hepatitis B e antigen (HBeAg) seroconversion of LdT treatment than other anti-HBV agents suggests a potential immunomodulatory effect. The aim of the study was to investigate the changes of regulatory T cell (Treg)/interleukin (IL)-17-producing CD4+T helper (Th17) balance during LdT treatment and to discuss the relationship of Treg/Th17 balance with HBeAg change in HBeAg-positive chronic hepatitis B (CHB) patients receiving LdT antiviral treatment...
June 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28590325/uptake-of-and-factors-associated-with-direct-acting-antiviral-therapy-among-patients-in-the-chronic-hepatitis-cohort-study-2014-to-2015
#16
Philip R Spradling, Jian Xing, Loralee B Rupp, Anne C Moorman, Stuart C Gordon, Mei Lu, Eyasu H Teshale, Joseph A Boscarino, Mark A Schmidt, Yihe G Daida, Scott D Holmberg
BACKGROUND: Limited information is available describing the uptake of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection among patients in general US health care settings. We determined the proportion of HCV-infected patients in the Chronic Hepatitis Cohort Study prescribed DAAs in 2014, who initiated treatment and identified characteristics associated with treatment initiation. METHODS: Uptake was defined as the proportion of HCV-infected patients with at least 1 clinical encounter in 2013 who were prescribed a DAA regimen during 2014 and initiated the regimen by August 2015...
June 5, 2017: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/28588691/chronic-hepatitis-b-patients-with-high-liver-fibrosis-levels-should-receive-antiviral-treatment
#17
Xu Li, Qinglong Jin, Hongqin Xu, Zetian Zhang, Hongjie Zhou, Dongqing Yan, Dongmei Li, Pujun Gao, Junqi Niu
The present study aimed to evaluate improvements in liver stiffness (LS) measured by transient elastography (TE) and associated factors in Chinese patients with chronic hepatitis B (CHB) treated with entecavir (ETV). A total of 190 consecutive CHB patients who received entecavir therapy and two LS measurements (LSMs) were enrolled in this retrospective study (average age, 47 years; 137 males [72.1%]), including 111 patients without liver cirrhosis (group 0) and 79 patients with liver cirrhosis (group 1). Each patient received LSM twice with an interval of six months...
June 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/28585404/frequency-of-and-factors-associated-with-hepatitis-b-virus-reactivation-in-hepatitis-c-patients-treated-with-all-oral-direct-acting-antivirals-analysis-of-a-japanese-prospective-cohort
#18
Akira Doi, Ryotaro Sakamori, Yuki Tahata, Ayako Urabe, Naoki Morishita, Ryoko Yamada, Kunimaro Furuta, Takahiro Kodama, Hayato Hikita, Takayuki Yakushijin, Kazuyoshi Ohkawa, Akira Kaneko, Yasuharu Imai, Tomohide Tatsumi, Tetsuo Takehara
AIM: Several case reports have shown that hepatitis B virus (HBV) reactivation developed in hepatitis C patients with a current or previous HBV infection during direct-acting antiviral (DAA) treatment, which led to severe hepatitis or death in some cases. However, its precise frequency and risk factors are not entirely clear. We analyzed a prospective cohort. METHODS: We analyzed HBV reactivation in 461 consecutive hepatitis C patients who received 12 weeks of ledipasvir/sofosbuvir for genotype 1 or sofosbuvir plus ribavirin for genotype 2 at multiple centers...
June 5, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/28584155/capsid-assembly-modulators-have-a-dual-mechanism-of-action-in-primary-human-hepatocytes-infected-with-hepatitis-b-virus
#19
Jan Martin Berke, Pascale Dehertogh, Karen Vergauwen, Ellen van Damme, Wendy Mostmans, Koen Vandyck, Frederik Pauwels
Hepatitis B Virus (HBV) capsid assembly is a critical step in the propagation of the virus mediated by the core protein. Due to its multiple functions in the viral life cycle, core became an attractive target for new antiviral therapies. Capsid assembly modulators (CAMs) accelerate the kinetics of capsid assembly and prevent encapsidation of the polymerase-pregenomic RNA (pol-pgRNA) complex thereby blocking viral replication. CAM JNJ-632 is a novel and potent inhibitor of HBV replication in vitro across genotypes A-D...
June 5, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28581644/hepatitis-b-surface-antigen-loss-and-sustained-viral-suppression-in-asian-chronic-hepatitis-b-patients-a-community-based-real-world-study
#20
Robert J Wong, My T Nguyen, Huy N Trinh, Chuck Chan, Andrew Huynh, My Tops Ly, Huy A Nguyen, Khanh K Nguyen, Sharon Torres, Jenny Yang, Benny Liu, Ruel T Garcia, Taft Bhuket, Rachel Baden, Brian Levitt, Eduardo da Silveira, Robert G Gish
Community-based real-world outcomes on effectiveness of antiviral therapies for chronic hepatitis B virus (CHB) in Asians are limited. Whether hepatitis B surface antigen (HBsAg) loss correlates with undetectable virus and alanine aminotransferase (ALT) normalization on treatment or what predicts risk of seroreversion or detectable virus after stopping therapy is unclear. We aim to evaluate rates and predictors of HBsAg loss, seroconversion, ALT normalization and undetectable HBV DNA, including HBsAg seroreversion or re-emergence of HBV DNA among Asian CHB patients...
June 5, 2017: Journal of Viral Hepatitis
keyword
keyword
32508
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"